PPARγ and glucose homeostasis

Annual Review of Nutrition

Volumn 22, Issue , 2002, Pages 167-197

  Picard, Frédéric ^a   Auwerx, Johan ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Diabetes; Insulin resistance; Lipids; Nuclear receptors; Transcription

Indexed keywords

5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; FARGLITAZAR; FENOFIBRATE; GW 0072; INSULIN; LG 100641; MEGLITINIDE; METFORMIN; NC 2100; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; REGLITAZAR; RETINOID X RECEPTOR; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TESAGLITAZAR; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; BINDING KINETICS; CELL DIFFERENTIATION; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FLUID RETENTION; GENE INDUCTION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HETEROZYGOSITY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER FAILURE; LUNG EDEMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MICE; MICE, KNOCKOUT; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

ANIMALIA;

EID: 0036399805     PISSN: 01999885     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.nutr.22.010402.102808     Document Type: Review

References (233)

1. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK. 1997. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem. 272:5128-32
2. Al-Salman J, Arjomand H, Kemp DG, Mittal M. 2000. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann. Intern. Med. 132:121-24
3. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, et al. 2000. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26:76-80
4. Arakawa K, Ishihara T, Aoto M, Inamasu M, Saito A, Ikezawa K. 1998. Actions of novel antidiabetic thiazolidinedione, T-174, in animal models of non-insulin-dependent diabetes mellitus (NIDDM) and in cultured muscle cells. Br. J. Pharmacol. 125:429-36
5. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, et al. 1999. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257:79-83
6. American Diabetes Association. 1998. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 21: 296-309
7. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, et al. 1997. Tissue distribution and quantification of the expression of PPARs and LXRα in humans: No alterations in adipose tissue of obese and NIDDM patients. Diabetes 48:1319-27
8. Auwerx J. 1999. PPARγ, the ultimate thrifty gene. Diabetologia 42:1033-49
9. Bakopanos E, Silva JE. 2000. Thiazolidinediones inhibit the expression of beta3-adrenergic receptors at a transcriptional level. Diabetes 49:2108-15
10. Banerji MA, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. 1995. Does intra-abdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive? Diabetes 44:141-46
11. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, et al. 1999. PPARgamma is recruited for placental, cardiac, and adipose tissue development. Mol. Cell. 4: 585-95
12. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, et al. 1999. Dominant negative mutations in human PPAR-gamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-83
13. Baumann CA, Chokshi N, Saltiel AR, Ribon V. 2000. Cloning and characterization of a functional peroxisome proliferator activator receptor-gamma-responsive element in the promoter of the CAP gene. J. Biol. Chem. 275:9131-35
14. Baumann CA, Ribon V, Kanzaki M, Thurmond DC, Mora S, et al. 2000. CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature 407:202-7
15. Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, et al. 1998. Association of the Pro12Ala variant in peroxisome proliferator-activated receptor gamma2 gene with obesity in two Caucasian populations. Diabetes 47:1806-8
16. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7:947-53
17. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, et al. 1998. Novel PPARγ and PPARδ ligands produce distinct physiological effects: PPARγ activation correlates with antidiabetic activity. J. Biol. Chem. 274:6718-25
18. Berkowitz K, Peters R, Kjos SL, Goico J, Marroquin A, et al. 1996. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes 45:1572-79
19. Bloomgarden ZT. 1999. American Diabetes Association Annual Meeting, 1998. Treatment of type 2 diabetes. Diabetes Care 22:170-74
20. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. 1995. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α -β, and γ in the adult rat. Endocrinology 137:354-66
21. Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, et al. 1999. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 48: 1415-24
22. Burant CF, Sreenan S, Hirano K-I, Tai TAC, Lohmiller J, et al. 1997. Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100:2900-8
23. Burkey BF, Dong M, Gagen K, Eckhardt M, Dragonas N, et al. 2000. Effects of pioglitazone on promoting energy storage, not expenditure, in brown adipose tissue of obese fa/fa Zucker rats: Comparison to CL 316,243. Metabolism 49:1301-8
24. Castillo G, Brun RP, Rosenfield JK, Hauser S, Park CW, et al. 1999. An adipogenic cofactor bound by the differentiation domain of PPARgamma. EMBO J. 18:3676-87
25. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. 1997. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J. Clin. Invest. 100:530-37
26. Cha BS, Ciaraldi TP, Carter L, Nikoulina SE, Mudaliar S, et al. 2001. Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia 44:444-52
27. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, et al. 2000. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 106:1221-28
28. Chaput E, Saladin R, Silvestre M, Edgar AD. 2000. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem. Biophys. Res. Commun. 271:445-50
29. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, et al. 2001. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 7:161-71
30. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA. 1990. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39: 1056-62
31. Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, et al. 2001. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl. Acad. Sci. USA 98:2610-15
32. Clement K, Hercberg S, Passinge B, Galan P, Varroud-Vial M, et al. 2000. The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int. J. Obes. Relat. Metab. Disord. 24:391-93
33. Cobb JE, Blanchard SG, Boswell EG, Brown KK, Charifson PS, et al. 1998. N-(2-benzoylphenyl)-L-tyrosine PPAR-gamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent. J. Med. Chem. 41:5055-69
34. Cohen B, Novick D, Rubinstein M. 1996. Modulation of insulin activities by leptin. Science 274:1185-88
35. Collins JL, Blanchard SG, Boswell GE, Charifson PS, Cobb JE, et al. 1998. N-(2-benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety. J. Med. Chem. 41:5037-54
36. Dana SL, Hoener PA, Bilakovics JM, Crombie DL, Ogilvie KM, et al. 2001. Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rats. Metabolism 50:963-71
37. Davies PJ, Berry SA, Shipley GL, Eckel RH, Hennuyer N, et al. 2001. Metabolic effects of rexinoids: Tissue-specific regulation of lipoprotein lipase activity. Mol. Pharmacol. 59:170-76
38. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, et al. 2001. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50:1863-71
39. De Vos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, et al. 1996. Thiazolidinediones repress ob gene expression via activation of PPARγ. J. Clin. Invest. 98:1004-9
40. Deeb S, Fajas L, Nemoto M, Laakso M, Fujimoto W, Auwerx J. 1998. A Pro 12 Ala substitution in the human peroxisome proliferator-activated receptor gamma2 is associated with decreased receptor activity, improved insulin sensitivity, and lowered body mass index. Nat. Genet. 20: 284-87
41. DeFronzo RA. 1988. The Triumvirate: Beta-cell, muscle, liver: A collusion responsible for NIDDM. Diabetes 37:667-87
42. DeFronzo RA. 2000. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 133:73-74
43. Desvergne B, Wahli W. 1999. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr. Rev. 20:649-88
44. Digby JE, Montague CT, Sewter CP, Sanders L, Wilkison WO, et al. 1997. Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Diabetes 47:138-41
45. Douglas JA, Erdos MR, Wanatabe RM, Braun A, Johnston CI, et al. 2001. The peroxisome proliferator-activated receptorgamma Pro12Ala variant: Association with type 2 diabetes and trait differences. Diabetes 50:886-90
46. Dowell P, Ishmael JE, Avram D, Peterson VJ, Nevrivy DJ, Leid M. 1999. Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein. J. Biol. Chem. 274:15901-7
47. Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vandewalle B, et al. 2000. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 43:1165-69
48. Eckersley RM. 2001. Losing the battle of the bulge: Causes and consequences of increasing obesity. Med. J. Aust. 174:590-92
49. Ek J, Urhammer SA, Sorensen TIA, Andersen T, Auwerx J, Pedersen O. 1999. Homozygosity of the Pro12Ala variant of the peroxisome proliferator activated receptor γ2 (PPARγ2): Divergent modulating effects on body mass index in obese and lean men of Caucasian origin. Diabetologia 42:892-95
50. Emilsson V, O'Dowd J, Wang S, Liu YL, Sennitt M, et al. 2000. The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. Metabolism 49:1610-15
51. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B. 2001. Rat PPARs: Quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142:4195-202
52. Evans DJ, Pritchard-Jones K, Trotman-Dickenson B. 1986. Insulin oedema. Postgrad. Med. J. 62:665-68
53. Fahmi H, Di Battista JA, Pelletier JP, Mineau F, Ranger P, Martel-Pelletier J. 2001. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum. 44:595-607
54. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, et al. 1997. Organization, promoter analysis and expression of the human PPARγ gene. J. Biol. Chem. 272:18779-89
55. Fajas L, Debril MB, Auwerx J. 2001. Peroxisome proliferator-activated receptorgamma: From adipogenesis to carcinogenesis. J. Mol. Endocrinol. 27:1-9
56. Fajas L, Fruchart JC, Auwerx J. 1998. PPARγ3 mRNA: A distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett. 438:55-60
57. Ferrannini E. 1998. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: Problems and prospects. Endocr. Rev. 19:477-90
58. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. 1983. Effect of fatty acids on glucose production and utilization in man. J. Clin. Invest. 72:1737-47
59. Fiedorek FT, Wilson GG, Frith L, Patel J, Abou-Donia M. 2000. Monotherapy with GI262570, a tyrosine-based nonthiazolidinedione PPARγ agonist, improves metabolic control in type 2 diabetes mellitus patients. Diabetes 49:157 (abstract)
60. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, et al. 2001. β-cell mass dynamics in Zucker diabetic fatty rats: Rosiglitazone prevents the rise in net cell death. Diabetes 50:1021-29
61. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. 2000. Effects of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA 283:1695-702
62. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 1995. 15-Deoxy-A12,14 prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-12
63. Forman LM, Simmons DA, Diamond RH. 2000. Hepatic failure in a patient taking rosiglitazone. Ann. Intern. Med. 132:118-21
64. Frias JP, Yu JG, Kruszynska YT, Olefsky JM. 2000. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 23: 64-69
65. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. 1988. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-58
66. Fukui Y, Masui S, Osada S, Umesono K, Motojima K. 2000. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes 49:759-67
67. Gale EA. 2001. Lessons from the glitazones: A story of drug development. Lancet 357:1870-75
68. Gampe RTJ, Montana VG, Lambert MH, Miller AB, Bledsoe RK, et al. 2000. Asymmetry in the PPAR gamma-RXR alpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell. 5:545-55
69. Garg A, Peshock RM, Fleckenstein JL. 1999. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J. Clin. Endocrinol. Metab. 84:170-74
70. Gelman L, Zhou G, Fajas L, Raspe E, Fruchart JC, Auwerx J. 1999. p300 interacts with the N- and C-terminal part of PPARγ2 in a ligand-independent and -dependent manner respectively. J. Biol. Chem. 274:7681-88
71. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, et al. 1997. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46:433-39
72. Glass CK, Rosenfeld MG. 2000. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14:121-41
73. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. 1999. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 48:437-41
74. Gorson DM. 1999. Significant weight gain with Rezulin therapy. Arch. Intern. Med. 159:99
75. Haffner SM, Howard G, Mayer E, Bergman RN, Savage PJ, et al. 1997. Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: The Insulin Resistance Atherosclerosis Study. Diabetes 46:63-69
76. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, et al. 1995. Weightreducing effects of the plasma protein encoded by the obese gene. Science 269: 543-46
77. Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, et al. 1997. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46:1393-99
78. Hallakou S, Foufelle F, Doare L, Kergoat M, Ferre P. 1998. Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation. Diabetologia 41:963-68
79. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, et al. 2000. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem. Biophys. Res. Commun. 271:212-16
80. Haskins JR, Rowse P, Rahbari R, de la Iglesia FA. 2001. Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch. Toxicol. 75:425-38
81. Heery DM, Kalkhoven E, Hoare S, Parker MG. 1997. A signature motif in transcriptional coactivators mediates binding to nuclear receptors. Nature 387:733-36
82. Heinlein CA, Ting HJ, Yeh S, Chang C. 1999. Identification of ARA70 as a ligandenhanced coactivator for the peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 274:16147-52
83. Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, et al. 1998. N-(2-benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem. 41:5020-36
84. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH. 1999. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc. Natl. Acad. Sci. USA 96:11513-18
85. Hill M, Young M, McCurdy C, Gimble J. 1997. Decreased expression of murine PPARγ in adipose tissue during endotoxinemia. Endocrinology 138:3073-76
86. Hirsch IB, Kelly J, Cooper S. 1999. Pulmonary edema associated with troglitazone therapy. Arch. Intern. Med. 159:1811
87. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, et al. 1994. Altered gene expression for tumor necrosis factor-α and its receptor during drug and dietary modulation of insulin resistance. Endocrinology 134:264-70
88. Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR. 1996. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc. Natl. Acad. Sci. USA 93:4948-52
89. Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW. 1998. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care 21:1462-69
90. Hotamisligil GS, Shargill NS, Spiegelman BM. 1993. Adipose tissue expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 259:87-91
91. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, et al. 2001. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126-33
92. Hsueh WC, Cole SA, Shuldiner AR, Beamer BA, Blangero J, et al. 2001. Interactions between variants in the beta3-adrenergic receptor and peroxisome proliferator-activated receptor-gamma2 genes and obesity. Diabetes Care 24:672-77
93. Hu E, Kim JB, Sarraf P, Spiegelman BM. 1996. Inhibition of adipogenesis through MAP-kinase mediated phosphorylation of PPARγ. Science 274:2100-3
94. IJima K, Yoshizumi M, Ako J, Eto M, Kim S, Hashimoto M. 1998. Expression of peroxisome proliferator activated receptor γ (PPARγ) in rat smooth muscle cells. Biochem. Biophys. Res. Commun. 247:353-56
95. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, et al. 1998. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes. N. Engl. J. Med. 338:867-72
96. Iwata M, Haruta T, Usui I, Takata Y, Takano A, et al. 2001. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptorgamma. Diabetes 50:1083-92
97. Kallen CB, Lazar MA. 1996. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. USA 93:5793-96
98. Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ. 1997. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389:374-77
99. Kausch C, Krutzfeldt J, Witke A, Rettig A, Bachmann O, et al. 2001. Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. Biochem. Biophys. Res. Commun. 280: 664-74
100. Kawai T, Takei I, Oguma Y, Ohashi N, Tokui M, et al. 1999. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 48:1102-7
101. Kelly IE, Han TS, Walsh K, Lean ME. 1999. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288-93
102. Kim HI, Kim JW, Kim SH, Cha JY, Kim KS, Ahn YH. 2000. Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes 49:1517-24
103. Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K, et al. 2000. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc. Natl. Acad. Sci. USA 97:14478-83
104. Kjellstedt A, Oakes N, Svensson L, Carlsson A-C, Ljung B. 2001. AZ 242, a novel PPARα/γ agonist, has potent and efficient insulin-sensitizing and antidyslipidemic properties in ob/ob mice and fa/fa Zucker rats. Diabetes 50(suppl 2):A121 (abstract)
105. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, et al. 1997. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. USA 94:4318-23
106. Kodera Y, Takeyama K, Murayama A, Suzawa M, Masuhiro Y, Kato S. 2000. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J. Biol. Chem. 275:33201-4
107. Koivisto VA. 1993. Insulin therapy in type II diabetes. Diabetes Care 16(Suppl 3):29-39
108. Koshida H, Shibata K, Kemetani T. 1998. Pleuropulmonary disease in a man with diabetes who was treated with troglitazone. N. Engl. J. Med. 339:1400-1
109. Kraegen EW, James DE, Jenkins AB, Chisholm DJ, Storlien LH. 1989. A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats. Metabolism 38:1089-93
110. Kruszynska YT, Mukherjee R, Jow L, Dana S, Paterniti JR, Olefsky JM. 1998. Skeletal muscle peroxisome proliferatoractivated receptor-γ expression in obesity and non-insulin-dependent diabetes mellitus. J. Clin. Invest. 101:543-48
111. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, et al. 1999. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell. 4:597-609
112. Kwon G, Xu G, Marshall CA, McDaniel ML. 1999. Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta12,14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor gamma activation and inos expression. J. Biol. Chem. 274:18702-8
113. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, et al. 1998. Diverse signalling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl. Acad. Sci. USA 95:2920-25
114. Lee MK, Miles PD, Khoursheed M, Gao KM, Moossa AR, Olefsky JM. 1994. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43:1435-39
115. Lefebvre AM, Laville M, Vega N, Riou JP, Van Gaal L, et al. 1998. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 47:98-103
116. Lefebvre A-M, Peinado-Onsurbe J, Leitersdorf I, Briggs MR, Paterniti JR, et al. 1997. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct, but complementary mechanism relative to fibrates. Arterioscler. Thromb. Vasc. Biol. 17:1756-64
117. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. 1997. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272:3406-10
118. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270:12953-56
119. Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J, Duez H, et al. 2000. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett. 473: 333-36
120. Lenhard JM, Kliewer SA, Paulik MA, Plunket KD, Lehmann JM, Weiel JE. 1997. Effects of troglitazone and metformin on glucose and lipid metabolism: Alterations of two distinct molecular pathways. Biochem. Pharmacol. 54:801-8
121. Loviscach M, Rehman N, Carter L, Mudaliar S, Mohadeen P, et al. 2000. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: Relation to insulin action. Diabetologia 43: 304-11
122. Lowell BB. 1999. PPARgamma: An essential regulator of adipogenesis and modulator of fat cell function. Cell 99:239-42
123. Luan J, Browne PO, Harding AH, Halsall DJ, O'Rahilly S, et al. 2001. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 50:686-89
124. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, et al. 2001. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-99
125. Maggi LB Jr, Sadeghi H, Weigand C, Scarim AL, Heitmeier MR, Corbett JA. 2000. Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: Evidence for heat shockdependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 49:346-55
126. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, et al. 1998. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 128:176-85
127. Majer M, Popov KM, Harris RA, Bogardus C, Prochazka M. 1998. Insulin downregulates pyruvate dehydrogenase kinase (PDK) mRNA: Potential mechanism contributing to increased lipid oxidation in insulin-resistant subjects. Mol. Genet. Metab. 65:181-86
128. Martin G, Schoonjans K, Lefebvre A, Staels B, Auwerx J. 1997. Coordinate regulation of the expression of the fatty acid transport protein (FATP) and acyl CoA synthetase genes by PPARα and PPARγ activators. J. Biol. Chem. 272:28210-17
129. Martin G, Schoonjans K, Staels B, Auwerx J. 1998. PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 137:75-80
130. Mauriege P, Imbeault P, Langin D, Lacaille M, Almeras N, et al. 1999. Regional and gender variations in adipose tissue lipolysis in response to weight loss. J. Lipid Res. 40:1559-71
131. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, et al. 2000. Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int. J. Obes. Relat. Metab. Disord. 24:195-99
132. Memon RA, Tecott LH, Nonogaki K, Beigneux A, Moser AH, et al. 2000. Upregulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: Troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 141:4021-31
133. Miles PD, Barak Y, He W, Evans RM, Olefsky JM. 2000. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest. 105: 287-92
134. Miles PD, Higo K, Romeo OM, Lee MK, Rafaat K, Olefsky JM. 1998. Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance. Diabetes 47:395-400
135. Miles PD, Romeo OM, Higo K, Cohen A, Rafaat K, Olefsky JM. 1997. TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 46:1678-83
136. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, et al. 2001. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-19
137. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, et al. 1998. Life without fat: A transgenic mouse. Genes Dev. 12:3168-81
138. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, et al. 2001. The Pro12Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: Possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50:891-94
139. Mori Y, Kim-Motoyama H, Katakura T, Yasuda K, Kadowaki H, et al. 1998. Effect of the Pro12Ala variant of the human peroxisome proliferator activated receptor γ2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem. Biophys. Res. Commun. 251:195-98
140. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, et al. 1999. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22: 908-12
141. Morrison RF, Farmer SR. 2000. Hormonal signaling and transcriptional control of adipocyte differentiation. J. Nutr. 130:3116S-21S
142. Mudaliar S, Henry RR. 2001. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu. Rev. Med. 52:239-57
143. Mukherjee R, Davies PAJ, Crombie DL, Bischoff ED, Cesario RM, et al. 1997. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386:407-10
144. Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, et al. 2000. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol. Endocrinol. 14:1425-33
145. Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, et al. 1998. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor α and γ. Effect of PPARα activation on normal lipid metabolism in liver of Zucker fatty rats. Diabetes 47:1841-47
146. Nagy L, Tontonez P, Alvarez JG, Chen H, Evans RM. 1998. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93:229-40
147. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. 1994. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331:1188-93
148. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, et al. 1998. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor γ. Nature 395:137-43
149. Oakes ND, Camilleri S, Furler SM, Chisholm DJ, Kraegen EW. 1997. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue availability in the rat. Metabolism 46:935-42
150. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW. 1994. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203-10
151. Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, et al. 1999. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. USA 96:6102-6
152. Ogawa J, Takahashi S, Fujiwara T, Fukushige J, Hosokawa T, et al. 1999. Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. Life Sci. 65:1287-96
153. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, et al. 1998. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101:1354-61
154. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, et al. 2001. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA 98:5306-11
155. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. 1995. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-57
156. Perissi V, Staszewski LM, McInerney EM, Kurokawa R, Krones A, et al. 1999. Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev. 13:3198-208
157. Perreault M, Marette A. 2001. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat. Med. 7: 1138-43
158. Picard F, Kapur S, Perreault M, Marette A, Deshaies Y. 2001. Nitric oxide mediates endotoxin-induced hypertriglyceridemia through its action on skeletal muscle lipoprotein lipase. FASEB J. 15:1828-30
159. Pihlajamaki J, Miettinen R, Valve R, Karjalainen L, Mykkanen L, et al. 2000. The Pro12A1a substitution in the peroxisome proliferator activated receptor gamma 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly
160. Pilon G, Penfomis P, Marette A. 2000. Nitric oxide production by adipocytes: A role in the pathogenesis of insulin resistance? Horm. Metab. Res. 32:480-84
161. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. 1998. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829-39
162. Randle PJ. 1998. Regulatory interactions between lipids and carbohydrates: The glucose fatty acid cycle after 35 years. Diabetes Metab. Rev. 14:263-83
163. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. 2000. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43:278-84
164. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. 2001. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 24:1226-32
165. Ravi TS, Nelli P, Rai P, Kundaje GN. 1991. Insulin oedema: An uncommon complication of insulin therapy. J. Assoc. Physicians India 39:411-12
166. Reilly CM, Oates JC, Sudian J, Crosby MB, Halushka PV, Gilkeson GS. 2001. Prostaglandin J(2) inhibition of mesangial cell iNOS expression. Clin. Immunol. 98:337-45
167. Ribon V, Johnson JH, Camp HS, Saltiel AR. 1998. Thiazolidinediones and insulin resistance: Peroxisome proliferatoractivated receptor γ activation stimulates expression of the CAP gene. Proc. Natl. Acad. Sci. USA 95:14751-56
168. Ricquier D, Bouillaud F. 2000. Mitochondrial uncoupling proteins: From mitochondria to the regulation of energy balance. J. Physiol. 529 Pt 1:3-10
169. Rieusset J, Andreelli D, Auboeuf D, Roques P, Valier P, et al. 1999. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor γ in human adipocytes. Diabetes 48:699-705
170. Rieusset J, Auwerx J, Vidal H. 1999. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem. Biophys. Res. Commun. 265:265-71
171. Ringel J, Engeli S, Distler A, Sharma AM. 1999. Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus. Biochem. Biophys. Res. Commun. 254:450-53
172. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. 1998. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N. Engl. J. Med. 339:953-59
173. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, et al. 2001. A unique PPAR-gamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell. 8:737-47
174. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, et al. 1999. PPARgamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4:611-17
175. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. 2000. Transcriptional regulation of adipogenesis. Genes Dev. 14: 1293-307
176. Schaffler A, Barth N, Schimtz G, Zietz B, Pallizsch KD, Scholmerich J. 2001. Frequency and significance of Pro12Ala and Pro 115Gln polymorphism in gene for peroxisome proliferator-activated receptorgamma regarding metabolic parameters in a Caucasian cohort. Endocrine 14:369-73
177. Schoonjans K, Martin G, Staels B, Auwerx J. 1997. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 8:159-66
178. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman R, Briggs M, et al. 1996. PPARα and PPARγ activators direct a tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15:5336-48
179. Schoonjans K, Watanabe M, Suzuki H, Mahfoudi A, Krey G, et al. 1995. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J. Biol. Chem. 270:19269-76
180. Schreyer SA, Chua SC Jr, LeBoeuf RC. 1998. Obesity and diabetes in TNF-alpha receptor-deficient mice. J. Clin. Invest. 102:402-11
181. Schwartz S, Raskin P, Fonseca V, Graveline JF. 1998. Effect of troglitazone in insulin-treated patients with type II diabetes. N. Engl. J. Med. 338:861-66
182. Shibata T, Matsui K, Nagao K, Shinkai H, Yonemori F, Wakitani K. 1999. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidininedione derivative. Eur. J. Pharmacol. 364:211-19
183. Shibuya A, Watanabe M, Fujita Y, Saigenji K, Kuwao S, et al. 1998. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 21:2140-43
184. Shimabukuro M, Zhou YT, Lee Y, Unger RH. 1998. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J. Biol. Chem. 273: 3547-50
185. Shimizu H, Tsuchiya T, Sato N, Shimomura Y, Kobayashi I, Mori N. 1998. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 21:1470-74
186. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, et al. 1998. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: A model for congenital generalized lipodystrophy. Genes Dev. 12:3182-94
187. Singh Ahuja H, Liu S, Crombie DL, Boehm M, Leibowitz MD, et al. 2001. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol. Pharmacol. 59:765-73
188. Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, et al. 1997. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with noninsulin-dependent diabetes. Clin. Pharmacol. Ther. 62:194-202
189. Smith U, Gogg S, Johansson A, Olausson T, Rotter V, Svalstedt B. 2001. Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB J. 15:215-20
190. Spiegelman BM. 1998. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-14
191. Stefan N, Fritsche A, Haring HU, Stumvoli M. 2001. Effects of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene. Diabetes 50: 1143-48
192. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, et al. 2001. The hormone resistin links obesity to diabetes. Nature 409:307-12
193. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. 1992. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203
194. Swarbrick MM, Chapman CM, McQuillan BM, Hung J, Thompson PL, Beilby JP. 2001. A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma2 is associated with combined hyperlipidemia in obesity. Eur. J. Endocrinol. 144:277-82
195. Szalkowski D, White-Carrington S, Berger J, Zhang B. 1995. Antidiabetic thiazolidinediones block the inhibitory effects of TNFα on differentiation, insulin stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 136: 1474-81
196. Temple R, Ellenberg SS. 2000. Placebocontrolled trials and active-control trials in the evaluation of new treatment. I. Ethical and scientific issues. Ann. Intern. Med. 133:455-63
197. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM. 1995. PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol. Cell. Biol. 15:351-57
198. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. 1994. mPPARγ2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8:1224-34
199. Tontonoz P, Hu E, Spiegelman BM. 1994. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79:1147-56
200. Treuter E, Albrektsen T, Johansson L, Leers J, Gustafsson JA. 1998. A regulatory role for RIP140 in nuclear receptor activation. Mol. Endocrinol. 12:864-81
201. Uchimura K, Nakamuta M, Enjoji M, Irie T, Sugimoto R, et al. 2001. Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. Hepatology 33:91-99
202. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. 1997. Protection from obesity-induced insulin resistance in mice lacking TNF- alpha function. Nature 389: 610-14
203. Ventre J, Doebber T, Wu M, MacNaul K, Stevens K, et al. 1997. Targeted disruption of the tumor necrosis factor-α gene: Metabolic consequences in obese and nonobese mice. Diabetes 46:1526-31
204. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, et al. 1996. Regulation of PPARγ gene expression by nutrition and obesity in rodents. J. Clin. Invest. 97:2553-61
205. Vidal-Puig AJ, Considine RV, JimenezLinan M, Werman A, Pories WJ, et al. 1997. Peroxisome proliferator-activated receptor gene expression in human tissues: Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99:2416-22
206. Vionnet N, El Hani H, Dupont S, Gallina S, Francke S, et al. 2000. Genomewide search for type 2 diabetes-susceptibility genes in French whites: Evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am. J. Hum. Genet. 67:1470-80
207. Voegel JJ, Heine MJS, Zechel C, Chambon P, Gronemeyer H. 1996. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 15: 3667-75
208. Wang Q, Bing C, Al-Barzanji K, Mossakowaska DE, Wang XM, et al. 1997. Interactions between leptin and hypothalamic neuropeptide Y neurons in the control of food intake and energy homeostasis in the rat. Diabetes 46:335-41
209. Watkins PB, Whitcomb RW. 1998. Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. 338:916-17
210. Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, et al. 2001. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 276:25651-53
211. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, et al. 2001. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142:1269-77
212. Weinstein SP, Holand A, O'Boyle E, Haber RS. 1993. Effects of thiazolidinediones on glucocorticoid-induced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle. Metabolism 42:1365-69
213. Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig A, Flier JS. 1997. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 272:20230-35
214. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, et al. 2001. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86:1930-35
215. Willson TM, Lambert MH, Kliewer SA. 2001. Peroxisome proliferator-activated receptor γ and metabolic disease. Annu. Rev. Biochem. 70:341-67
216. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. 2000. Addition of low-dose rosiglitazone to sulfonylureas therapy improves glycaemic control in type 2 diabetes patients. Diabet. Med. 17:40-47
217. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, et al. 2000. A synthetic antagonist for the peroxisome proliferatoractivated receptor gamma inhibits adipocyte differentiation. J. Biol. Chem. 275: 1873-77
218. Wu M, Ventre J, Moller DE, Doebber T. 1997. Correction of elevated glucose and triglycerides in Zucker diabetic fatty rats by thiazolidinediones parallels increased I-glycogen synthase and lipoprotein lipase activity in muscle and fat. Diabetes 46(Suppl. 1):237A
219. Wu Z, Xie Y, Morrison RF, Bucher NLR, Farmer SR. 1998. PPARγ induces the insulin-dependent glucose transporter GLUT4 in absence of C/EBPα during the conversion of 3T3 fibroblast into adipocytes. J. Clin. Invest. 101:22-32
220. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, et al. 2001. The mechanisms by which both heterozygous PPARgamma deficiency and PPAR-gamma agonist improve insulin resistance. J. Biol. Chem. 31:31
221. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, et al. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7:941-46
222. Yamauchi T, Waki H, Kamon J, Murakami K, Motojima K, et al. 2001. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J. Clin. Invest. 108:1001-13
223. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, et al. 2001. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J. Clin. Endocrinol. Metab. 86:3815-19
224. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. 2001. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: Comparison with PPAR-gamma activation. Diabetes 50:411-17
225. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, et al. 1997. Molecular scanning of the human peroxisome proliferator activated receptor gamma gene in diabetic Caucasians: Identification of a Pro12Ala PPARgamma 2 missense mutation. Biochem. Biophys. Res. Commun. 241:270-74
226. Yonemitsu S, Nishimura H, Shintani M, Inoue R, Yamamoto Y, et al. 2001. Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes 50:1093-101
227. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, et al. 1995. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270:23975-83
228. Zhang B, Szalkowski D, Diaz E, Hayes N, Smith R, Berger J. 1994. Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedione-derived antidiabetic agents in Chinese hamster ovary cells expressing human insulin receptor and L6 myotubes. J. Biol. Chem. 269:25735-41
229. Zhu Y, Kan L, Qi C, Kanwar YS, Yeldandi AV, et al. 2000. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J. Biol. Chem. 275:13510-16
230. Zhu Y, Qi C, Calandra C, Rao MS, Reddy J. 1996. Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor γ. Gene Expression 6:185-95
231. Zhu Y, Qi C, Korenberg JR, Chen X-N, Noya D, et al. 1995. Structural organization of mouse peroxisome proliferator activated receptor γ (mPPARγ) gene: Alternative promoter use and different splicing yield two mPPARγ isoforms. Proc. Natl. Acad. Sci. USA 92:7921-25
232. Zierath JR, Ryder JW, Doebber T, Woods J, Wu M, et al. 1998. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Endocrinology 139:5034-41
233. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG. 1999. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 84:272-78